Andrew Ng-Backed Jivi.ai Launches AI Platform for HMPV Risk Assessment

The initiative is backed by Andrew Ng, a renowned deep-learning pioneer and co-founder of Google Brain, who serves as both an investor and technical adviser.

Jivi.ai, a healthcare startup co-founded by former BharatPe Chief Product Officer Ankur Jain and GVK family promoter Sanjay Reddy, has introduced an AI-powered risk assessment platform for human metapneumovirus (HMPV).

The initiative is backed by Andrew Ng, a renowned deep-learning pioneer and co-founder of Google Brain, who serves as both an investor and technical adviser.

The platform leverages smartphone technology to analyze user symptoms and vital parameters, evaluating HMPV risk levels. Using the phone’s front camera as a contactless heart rate monitoring system, the app gathers vital signs and combines them with a voice or text-based interactive session to assess risk. Available in 14 languages, the app is offered free of charge globally.

“We’ve built this risk assessment tool to ensure preparedness in case the situation escalates into a possible pandemic. The first line of defence is providing accurate and timely information,” said Jain.

Jivi.ai’s underlying technology, Jivi MedX, is a large language model trained on extensive medical literature, research papers, and clinical notes.

Further, the model has achieved a 91.65% accuracy score across nine benchmark categories on the Open Medical LLM Leaderboard, surpassing similar models from Google and OpenAI. The startup emphasizes a strong medical presence, with doctors making up 40% of its team, including in-house surgeons and physicians who validate the platform’s outputs.

Everything You Need to Know About the Rising Virus - HMPV

Human Metapneumovirus (HMPV) is a respiratory virus that causes infections in the upper and lower respiratory tracts, similar to a cold. It typically surfaces in winter and early spring, paralleling the patterns of Respiratory Syncytial Virus (RSV) and the flu.

Although HMPV was first identified in 2001, evidence suggests it has been widespread since 1958, and it belongs to the Pneumoviridae family alongside RSV.

Is HMPV Similar to COVID-19?

HMPV and COVID-19 share similarities, including affecting respiratory health across all age groups, with heightened risks for children, the elderly, and those with weakened immune systems. Both viruses spread through respiratory secretions and contaminated surfaces, with seasonal infection patterns.

However, unlike COVID-19, there is no vaccine or specific antiviral treatment for HMPV, making preventive measures like hand hygiene and avoiding contact with the sick crucial.

Current Concerns & Precautions

Amid concerns about an HMPV outbreak in China, Indian health officials, including Dr. Atul Goel, assure there is no significant rise in respiratory outbreaks in India. He emphasized preparedness and recommended general precautions for respiratory health.

Moreover, he highlighted the importance of PCR testing for accurate HMPV diagnosis to manage potential healthcare system strain.

About Jivi.ai

Jivi, based in Gurugram, is leveraging AI to transform healthcare delivery in multiple ways.

The platform utilizes advanced algorithms to analyze patient data, enabling it to suggest potential diagnoses and improve the accuracy of early detection.

In addition, Jivi automates the creation of detailed health reports, helping healthcare professionals streamline documentation and reduce administrative burdens.

By automating routine administrative tasks, the startup allows healthcare providers to focus more on patient care, ultimately enhancing patient outcomes.

Stay tuned for more such updates on Digital Health News.